Premium
Evaluation of the Neuroprotective Efficacy of Newly Developed Oximes (K206, K269) and Currently Available Oximes (Obidoxime, HI‐6) in Cyclosarin‐Poisoned Rats
Author(s) -
Kassa Jiri,
Karasova Jana Zdarova,
Bajgar Jiri,
Tesarova Sandra,
Kuca Kamil,
Musilek Kamil
Publication year - 2009
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2008.00352.x
Subject(s) - neuroprotection , pharmacology , oxime , neurotoxicity , potency , chemistry , medicine , biochemistry , toxicity , organic chemistry , in vitro
The neuroprotective effects of newly developed oximes (K206, K269) and currently available oximes (obidoxime, HI‐6) in combination with atropine in rats poisoned with cyclosarin were studied. The cyclosarin‐induced neurotoxicity was monitored using a functional observational battery at 24 hr following cyclosarin challenge. The results indicate that a newly developed oxime K206 is able to counteract cyclosarin‐induced neurotoxicity while the neuroprotective potency of another newly developed oxime (K269) is negligible. The neuroprotective efficacy of K206 is markedly higher than commonly used obidoxime; nevertheless, its potency to eliminate cyclosarin‐induced neurotoxicity is slightly lower compared to the oxime HI‐6. Thus, a newly developed oxime K206 seems to be a better oxime for the antidotal treatment of cyclosarin poisonings than obidoxime due to higher neuroprotective potency although the oxime HI‐6 is still the most suitable oxime for the antidotal treatment of acute poisonings with cyclosarin.